StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
AGIOAGIOS PHARMACEUTICALS, INC.
stockpulse.co.kr
Nasdaq
$37.74▲ 2.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.24BShares out 59.5M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

8
  • 1d agoAfter-hours26.10.24 05:05
    4Ownership#●●●

    AGIOS PHARMACEUTICALS, INC.

    Sarah Gheuens, an insider at Agios Pharmaceuticals, Inc., filed a Form 4 report regarding changes in beneficial ownership of securities as of October 21, 2026. This filing serves as an official disclosure of the insider's updated stock holdings.…more

    $37.74+2.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 2d agoAfter-hours26.10.23 05:48
    144Ownership

    AGIOS PHARMACEUTICALS, INC.

    Sarah Gheuens, an executive at Agios Pharmaceuticals, has filed an SEC Form 144 to report a proposed sale of company stock. This is a standard filing disclosing an insider's plan to dispose of shares.…more

    $37.74+2.04%vs prev close
    View filingShare
  • 3d agoAfter-hours26.10.22 06:32
    144Ownership

    AGIOS PHARMACEUTICALS, INC.

    Sarah Gheuens, an executive at Agios Pharmaceuticals, Inc., has filed a Form 144 regarding the proposed sale of company securities. This is a standard regulatory filing disclosing an insider's plan to dispose of shares.…more

    $37.74+2.04%vs prev close
    View filingShare

7 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.8Pre-market26.10.08 20:00
    #●●●

    Agios to Host Third Quarter 2026 Financial Results Conference Call on Nov 5…more

    Agios Pharmaceuticals will host a conference call and live webcast on November 5, 2026, at 8:00 a.m. ET. The event will cover the company's third-quarter financial results and business highlights.…more

    $37.74+2.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 7.30Pre-market26.07.30 19:30

    ●●●●●●●● ●●●●● ●●●●●●

    아지오스는 주력 제품의 매출 성장과 함께 신약 후보물질의 라이선스 도입 및 임상 진전으로 파이프라인을 강화했습니다. FDA의 우선 심사 지정 등 주요 신약 개발 성과가 이어지며 향후 성장 기대감을 높였습니다.…more

    $37.74+2.04%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →